Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...

The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...

North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...

New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope. | New-look Novo is digging deeper into its metabolic roots with three ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

The FDA granted Aptitude its first 510(k) clearance for the next-generation Metrix COVID diagnostic that features three-times greater sensitivity with 30% faster results that its original emergency ...

Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. | Electra ...

Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseas ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...